How long does it take to lose weight on semaglutide?

Most people see measurable weight loss within 4 weeks of starting semaglutide, even on the low 0.25 mg starting dose. In the STEP 1 trial, participants lost approximately 2% of body weight by week 4 and 14.9% by week 68. The steepest weight loss occurs between months 2 and 6, once the maintenance dose of 2.4 mg is reached around week 17.

When does semaglutide start suppressing appetite?

Appetite suppression typically begins within 1 to 2 weeks of the first injection. Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and increasing satiety. Many users report feeling fuller sooner at meals and experiencing fewer cravings before any significant number appears on the scale.

Does semaglutide stop working after a year?

No. The STEP 5 trial followed participants on semaglutide 2.4 mg for 104 weeks (2 years) and found that weight loss of 15.2% was maintained throughout, with no evidence of tolerance or reduced effectiveness over time. Weight loss plateaus around week 60 to 68 but remains stable at that level with continued treatment.

What is the semaglutide dose escalation schedule?

The standard schedule is 0.25 mg weekly for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and 2.4 mg from week 17 onward. This gradual increase takes about 4 months to reach the full therapeutic dose and is designed to minimize nausea and other gastrointestinal side effects.

How much weight can you lose on semaglutide in 3 months?

By 3 months (week 12), participants in the STEP trials had lost approximately 6 to 8% of their baseline body weight. For a person starting at 100 kg (220 lbs), that is roughly 6 to 8 kg (13 to 18 lbs). Individual results vary based on starting weight, dose tolerance, diet, and physical activity level.

Do you regain weight after stopping semaglutide?

Yes. The STEP 4 trial showed that participants who stopped semaglutide regained approximately 6.9% of body weight over the following 48 weeks, reversing about two-thirds of the weight lost during the 20-week treatment period. Weight regain begins gradually about 4 to 6 weeks after discontinuation as appetite returns to pre-treatment levels.

Semaglutide for Weight Loss

How Long Does It Take for Semaglutide to Work?

15 min read|March 22, 2026

Semaglutide for Weight Loss

14.9% avg weight loss

In the STEP 1 trial, 1,961 adults taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks.

Wilding et al., NEJM, 2021

View as image

Semaglutide begins working within hours of the first injection. The GLP-1 receptor agonist binds to receptors in the brain and gut almost immediately, reducing appetite and slowing gastric emptying. But the question most people are actually asking is: when will I see results on the scale? The answer, drawn from six major randomized controlled trials involving over 20,000 participants, follows a predictable curve. If you are looking for a comprehensive overview of this drug, start with our guide to semaglutide for weight loss.

The short version: appetite changes show up within the first week. Measurable weight loss appears by week 4. The steepest rate of loss occurs between months 2 and 6. And maximum effect arrives somewhere around week 60 to 68, with the largest trial reporting an average loss of 14.9% of body weight at that point.^[1]

Key Takeaways

The STEP 1 trial (1,961 adults) recorded a mean body weight reduction of 14.9% at week 68 on semaglutide 2.4 mg, compared to 2.4% on placebo^[1]
Appetite suppression begins within the first 1 to 2 weeks, before measurable weight change appears on the scale
By week 4 on the starting dose (0.25 mg), participants in the STEP trials had already lost approximately 2 to 4% of baseline body weight
The STEP 5 trial showed semaglutide maintained 15.2% weight loss over 104 weeks (2 years), meaning the drug does not stop working with prolonged use^[2]
Half of all participants in STEP 1 lost 15% or more of their body weight, and 86.4% lost at least 5%^[1]
When people stopped semaglutide in the STEP 4 trial, they regained roughly two-thirds of the weight they had lost within the following 48 weeks^[5]

The First Four Weeks: Dose Escalation and Early Appetite Changes

Semaglutide treatment begins at 0.25 mg weekly, a dose that is subtherapeutic for weight loss. This low starting point exists to reduce gastrointestinal side effects, not to start losing weight. During this phase, the drug is already active in the body. GLP-1 receptors in the hypothalamus and brainstem begin responding, and most people notice reduced hunger and earlier fullness at meals within 7 to 14 days.

Weight change during this period is modest but real. In the STEP 1 trial, the first assessment at week 4 showed approximately 2% weight loss from baseline in the semaglutide group.^[1] That is roughly 2 to 4 pounds for a person starting at 220 pounds. The placebo group lost about 0.5% over the same period, meaning most of the early loss is attributable to the drug, not to the lifestyle intervention alone.

Gastrointestinal effects peak during dose increases. Nausea, the most common side effect, affected a significant portion of semaglutide users in the STEP trials, but was typically transient and mild to moderate in severity.^[1] For a detailed look at how the dose escalation schedule affects tolerability and timeline, see our dedicated guide.

Weeks 4 to 12: When the Scale Starts Moving

The dose doubles to 0.5 mg at week 5, then to 1.0 mg at week 9. This is the stretch where weight loss transitions from subtle to obvious. By week 12, data from the STEP program shows participants had lost approximately 6 to 8% of their baseline body weight on semaglutide, compared to about 2% on placebo.

This period also marks a shift in how food feels. Participants in the STEP 3 trial, which combined semaglutide with intensive behavioral therapy (30 counseling sessions over 68 weeks), reported that portion sizes decreased naturally and cravings diminished.^[4] The behavioral therapy group achieved 16.0% weight loss at 68 weeks versus 5.7% on placebo, showing that the drug's appetite effects compound with structured eating changes.

The rate of weight loss during weeks 4 to 12 is roughly 1 to 2% of body weight per month. For someone who started at 100 kg (220 lbs), that translates to losing about 1 to 2 kg (2 to 4 lbs) per month. The loss is not linear day to day, and weekly fluctuations from water retention, meals, and hormonal cycles are normal. The trend line matters more than any single weigh-in.

Individual variation during this phase is substantial. Some participants in the STEP trials lost over 10% by week 12, while others lost less than 3%. Factors that influence the speed of response include starting BMI, metabolic rate, adherence to lifestyle modifications, and individual GLP-1 receptor sensitivity. People with higher starting BMIs tend to lose more absolute weight but similar percentages. For a detailed breakdown of total weight loss numbers, see how much weight you can lose on semaglutide.

Months 3 to 6: The Steepest Part of the Curve

The maintenance dose of 2.4 mg is typically reached around week 17, after stepping through 1.7 mg at week 13. Once at the full dose, weight loss accelerates. The period between months 3 and 6 represents the steepest portion of the weight loss curve in every STEP trial.

In STEP 1, participants lost approximately 10 to 12% of their body weight by month 6 (week 24 to 28).^[1] That is an average rate of about 2% per month during this phase. The placebo group was losing less than 0.5% per month over the same interval.

The STEP 8 trial, which directly compared semaglutide 2.4 mg to liraglutide 3.0 mg (another GLP-1 agonist), found semaglutide produced 15.8% weight loss at 68 weeks versus 6.4% with liraglutide.^[6] By the 6-month mark, semaglutide users had already pulled ahead of liraglutide users by a wide margin, indicating that semaglutide's superior efficacy becomes apparent well before the 68-week endpoint.

This phase is also where changes in body composition become more pronounced. Clinical data shows semaglutide users lose both fat mass and lean mass, with fat accounting for roughly 60 to 75% of total weight lost.

Six Months to One Year: Approaching Maximum Effect

Weight loss continues beyond the 6-month mark, but the rate slows. The curve flattens from about 2% per month to closer to 1% per month, eventually reaching a plateau. In the STEP 1 trial, weight loss peaked around week 60, with the mean change from baseline reaching 14.9% at week 68.^[1]

The numbers at 68 weeks paint a clear picture of what half, two-thirds, and nearly all participants achieved: 86.4% lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%.^[1] These thresholds matter clinically. A 5% weight loss is associated with improvements in blood pressure, lipids, and glycemic control. At 10%, improvements in sleep apnea, joint pain, and fatty liver disease emerge. At 15%, some cardiovascular risk markers shift in ways that were previously only seen after bariatric surgery.

The SELECT trial, a cardiovascular outcomes study involving 17,604 patients with overweight or obesity and established cardiovascular disease, demonstrated a 20% reduction in the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke with semaglutide over a mean follow-up of 39.8 months (hazard ratio 0.80).^[3] These cardiovascular benefits took longer to materialize than weight loss, emerging after roughly 12 months of treatment and widening progressively from there.

For a visual comparison of weight loss at different time points, see our before and after data breakdown.

Beyond One Year: What the Two-Year Data Shows

A common concern is whether semaglutide stops working after a year. The STEP 5 trial answered this directly. Over 104 weeks (2 years), semaglutide 2.4 mg produced a mean weight loss of 15.2%, compared to 2.6% with placebo.^[2] Weight loss plateaued around weeks 60 to 68 and then remained stable through week 104. There was no evidence of the drug losing efficacy or tolerance developing over two years.

Of the 304 participants in STEP 5, 77.1% on semaglutide maintained at least 5% weight loss at the 2-year mark.^[2] Gastrointestinal adverse events were reported in 82.2% of the semaglutide group (vs. 53.9% on placebo), though the majority were mild to moderate and occurred primarily during dose escalation, not during the maintenance phase.

The 2-year data also suggests that semaglutide's metabolic benefits extend beyond the scale. Participants maintained improvements in waist circumference, blood pressure, lipid profiles, and C-reactive protein levels throughout the trial. For long-term safety data beyond clinical trials, see our review of semaglutide's 5+ years of safety data.

How the Dose Escalation Schedule Affects Your Timeline

The standard escalation for subcutaneous semaglutide follows a fixed schedule: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and the full 2.4 mg dose from week 17 onward. This means the full weight-loss dose is not reached until roughly the 4-month mark.

This schedule is not arbitrary. The STEP trials used it specifically to minimize GI side effects. In STEP 1, only 4.5% of participants discontinued due to gastrointestinal events.^[1] Faster dose escalation, attempted in some real-world settings, increases the risk of persistent nausea, vomiting, and treatment abandonment.

Some individuals respond strongly to lower doses. The 1.0 mg dose already provides clinically meaningful appetite suppression for many people, and weight loss at this level is well above placebo. Others do not reach their best response until 2.4 mg, and a newer dose of 7.2 mg is being evaluated. The STEP UP trial found that semaglutide 7.2 mg produced 20.7% mean weight loss over 72 weeks, exceeding the 2.4 mg dose.^[8]

The practical implication: do not judge semaglutide's effectiveness based on the first month. The starting dose is a tolerability ramp, not a therapeutic dose. Real assessment of whether the drug is working begins at week 12 to 16, once you have spent time on a therapeutic dose.

Does Oral Semaglutide Work on the Same Timeline?

Oral semaglutide (marketed as Rybelsus for diabetes, and recently approved as oral Wegovy for weight management) follows a similar biological timeline but with different dosing. The oral formulation requires an absorption enhancer (SNAC) and must be taken on an empty stomach with minimal water.

In a trial of oral semaglutide at 50 mg daily, participants achieved 15.1% weight loss at 68 weeks.^[7] The onset and trajectory of weight loss roughly mirrored the injectable formulation: appetite changes in the first 1 to 2 weeks, measurable loss by week 4, steepest loss between months 2 and 6, and plateau around month 12 to 15.

The main timeline difference is that oral dosing can be more sensitive to meal timing and adherence. Missing a dose or taking it incorrectly (with food or too much water) reduces absorption, which can slow weight loss. The oral form requires taking the tablet at least 30 minutes before the first food, drink, or other medication of the day, with no more than 4 ounces of plain water. These restrictions do not apply to the injectable version.

For people who cannot tolerate injections, the oral formulation provides a comparable weight loss timeline once adherence is established. For context on the differences between Ozempic and Wegovy, both of which contain semaglutide, see our comparison article. To understand what semaglutide is and how it works at the molecular level, see our mechanism guide.

What Happens to Weight After Stopping Semaglutide?

The STEP 4 trial provided the clearest picture of what happens when semaglutide is discontinued. After a 20-week run-in period where all participants received semaglutide and lost an average of 10.6% of their body weight, half were randomized to continue semaglutide while the other half switched to placebo. Over the next 48 weeks, the continuation group lost an additional 7.9% of body weight. The group that switched to placebo regained 6.9%.^[5]

The weight regain was not immediate. It followed a gradual upward trend starting about 4 to 6 weeks after discontinuation and continued steadily for the remaining 48 weeks of observation. Appetite returned to pre-treatment levels, hunger scores increased, and the caloric deficit that drove weight loss reversed.

This pattern has been confirmed in real-world data. A 2026 study analyzing post-semaglutide weight trajectories found that the majority of individuals regained a substantial portion of lost weight within one year of stopping treatment.^[9] This is consistent with the understanding that semaglutide treats obesity as a chronic condition; the drug manages it rather than curing it.

The biology behind this regain is straightforward. Semaglutide does not reset the body's weight set point. It suppresses appetite and slows gastric emptying for as long as it is present in the body. Once removed, the hormonal and neurological signals that drive hunger and energy storage return to their pre-treatment baseline. Body weight then drifts upward toward its previous equilibrium. This is not a failure of the drug; it is how chronic disease management works. Blood pressure medications behave the same way.

For more on this topic, see our full review of semaglutide weight regain after discontinuation and what happens when you stop taking semaglutide.

The Bottom Line

Semaglutide begins working within days at the biological level, with appetite suppression appearing in the first 1 to 2 weeks. Measurable weight loss shows up by week 4, accelerates between months 2 and 6 once the full dose is reached, and plateaus around month 15 at a mean of approximately 15% of body weight. Two-year data confirms the weight loss is sustained as long as treatment continues, but stopping the drug leads to gradual weight regain.